GlassScriptPhysician profile
Christopher Roger Miller
NPI 1811333917
$18,809.32
in general payments reported to CMS, 2019-2025
40 companies · $635 in 2025
The $635 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $75.40 · 2021: $15K · 2022: $783 · 2023: $670 · 2024: $755 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,060.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $15,000.00 | 2021 | |
| Astellas Pharma US INC | $585.17 | 2019-2025 | Xtandi, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $466.03 | 2021-2025 | Lynparza |
| Teleflex LLC | $303.29 | 2022-2025 | Urolift, Barrigel |
| Abbvie INC. | $259.16 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $236.94 | 2021-2025 | Keytruda, Lynparza |
| Urovant Sciences INC | $215.95 | 2021-2022 | |
| Boston Scientific Corporation | $192.60 | 2019-2022 | |
| Axonics, INC. | $149.81 | 2023-2024 | Axonics |
| Neotract INC. | $143.21 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $115.25 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $100.30 | 2023-2025 | Gemtesa, Orgovyx |
| 180 Medical, INC. | $80.00 | 2022-2024 | |
| Agiliti Surgical, INC. | $72.93 | 2023 | Cryocare Cs, Sonablate, Soltive |
| Dendreon Pharmaceuticals LLC | $72.41 | 2020-2023 | Provenge |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.